NRX Pharmaceuticals Inc.-CW22NRXPWPreferred / convertible
13F holders, Q4 2024 (December 31)5holders −3
0new positions
3sold out
$0.14avg. 13F price*
At the end of Q4 2024, 5 institutions reported holding NRX Pharmaceuticals Inc.-CW22 (NRXPW) in their 13F filings, down 3 from Q3 2024. 0 opened new positions and 3 sold out. The largest holders were Truist Financial Corp. ($5K), Virtu Financial LLC ($4K) and Wolverine Asset Management LLC ($664).
- Company
- NRX Pharmaceuticals Inc.-CW22
- CUSIP
- 629444118
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 3 | $802 |
All 13F filers, Q3 2024 → Q4 2024: 48,524 shares sold, net −48,524 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Truist Financial Corp. | — | No change | 38,965 | $5K |
| Virtu Financial LLC | — | Reduce -26.4% | 25,516 | $4K |
| Wolverine Asset Management LLC | — | Reduce -66.3% | 5,190 | $664 |
| UBS Group AG | — | Reduce -74.4% | 3,911 | $501 |
| Tower Research Capital LLC (TRC) | — | No change | 15 | $2 |
"% of holder's portfolio" is NRXPW's weight in each manager's 13F, not the share of NRX Pharmaceuticals Inc.-CW22 the manager owns.